Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines
US6310208A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 6, 1998 |
| Grant date | Oct 30, 2001 |
| Priority date | — |
| Expiry date | Jan 6, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Since the compounds in accordance with the invention can bind to serotonin receptors (5HT.sub.2), they are especially suitable for the treatment or prevention of central nervous disorders such as depressions, bipolar disorders, anxiety states, sleep and sexual disorders, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or pain of a different kind, personality disorders or obsessive-compulsive disorders, social phobias or panic attacks, mental organic disorders, mental disorders in childhood, aggressivity, age-related memory disorders and behavioral disorders, addiction, obesity, bulimia etc., nervous system damage caused by trauma, stroke, neurodegenerative diseases etc.; cardiovascular disorders such as hypertension, thrombosis, stroke etc.; and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.